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ExtrapolationApproaches to assess the role of absorption, metabolism and excretion of cosmetic ingredients that are based on
the integration of different in vitro data are important for their safety assessment, speciﬁcally as it offers an
opportunity to reﬁne that safety assessment. In order to estimate systemic exposure (AUC) to aromatic amine
hair dyes following typical product application conditions, skin penetration and epidermal and systemic meta-
bolic conversion of the parent compound was assessed in human skin explants and human keratinocyte
(HaCaT) and hepatocyte cultures. To estimate the amount of the aromatic amine that can reach the general
circulation unchanged after passage through the skin the following toxicokinetically relevant parameters were
applied: a) Michaelis–Menten kinetics to quantify the epidermal metabolism; b) the estimated keratinocyte
cell abundance in the viable epidermis; c) the skin penetration rate; d) the calculated Mean Residence Time in
the viable epidermis; e) the viable epidermis thickness and f) the skin permeability coefﬁcient. In a next step,
in vitro hepatocyte Km and Vmax values andwhole livermass and cell abundancewere used to calculate the scaled
intrinsic clearance, whichwas combinedwith liver blood ﬂow and fraction of compoundunbound in the blood to
give hepatic clearance. The systemic exposure in the general circulation (AUC) was extrapolated using internal
dose and hepatic clearance, and Cmax was extrapolated (conservative overestimation) using internal dose and
volume of distribution, indicating that appropriate toxicokinetic information can be generated based solely on
in vitro data. For the hair dye, p-phenylenediamine, these data were found to be in the same order of magnitude
as those published for human volunteers.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
We have used in vitromodels to predict the absorption, metabolism
and excretion (AME) properties of a number of aromatic amine hair dye
ingredients. The traditional in vivomodel to analyze systemic exposure
involves oral, intravenous and dermal application of a compound (shaved
skin of a rat), followed by measurement of plasma concentrations andnd Accreditation of Laboratory
; AEP, 2-amino-5-ethylphenol;
sol; Amtabs, amount absorbed;
ncentration; DKFZ, Deutsches
t; eq, equivalent (radioactivity
yrazole; CLH, hepatic clearance;
; MRT,mean residence time; kp,
quadrupole time-of-ﬂight; RAD,
e-2,5-diamine; CLT, total clear-
ribution.
n Business Center, 8700 Mason
).
. This is an open access article underexcretion in urine and feces of parent compound and its metabolites
(OECD TG427, 2004). However, in vitromethods can be used to provide
information that is needed to help with safety assessment. The types of
questions that should be answered include: what is the systemic expo-
sure to the chemical and itsmetabolites?Does the skin contribute to the
ﬁrst pass metabolism of the compound? If so, what are the metabolites
formed in the skin? Is the compound activated or deactivated by skin
metabolism? Here, we report the AME properties of a number of aro-
matic amine hair dye ingredients in vitro and in vivo and show how a
combination of in vitro assays may be used to assess skin metabolism
and absorption into the plasma, aswell as hepaticmetabolism, to ﬁnally
estimate the systemic circulatory exposure of the parent compound.
The models include an ex vivo skin diffusion model for dermal absorp-
tion and metabolism, human epidermal keratinocytes for dermal me-
tabolism, and human hepatocytes for hepatic metabolism. As a ﬁrst
step, the amount of the parent hair dye surviving epidermalmetabolism
and reaching the general circulation was estimated. The second step
was to estimate the systemic exposure using a calculated hepatic clear-
ance. Finally, standard pharmacokinetic parameters were applied tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the systemic exposure to the parent compound.
We have used the static skin absorption model to mimic dermal
absorption in vitro (OECD TG428, 2004) and assessed the systemic
availability of the aromatic amine hair dyes via the dermal route. In
addition, we have determined the metabolism kinetics of the hair dye
compounds in monolayer cultures of the human keratinocyte cell line,
HaCaT (Boukamp et al., 1988). This cell line represents the major
metabolic cell type in the skin and enables investigation of compound
metabolism in a higher throughput format than excised skin ex vivo.
Furthermore, HaCaT cells are an appropriate tool to study human skin
metabolism, especially since these cells exhibit a capacity toN-acetylate
aromatic aminehair dye precursors known to be relevant in human skin
(Eggenreich et al., 2004; Götz et al., 2012a, 2012b; Kawakubo et al.,
2000; Kawakubo and Ohkido, 1998). There are numerous drugmetabo-
lizing enzymes in the skin, albeit with much lower levels of phase 1
activities than the liver (Oesch et al., 2007; Götz et al., 2012a). How-
ever, unlike phase 1 activities, phase 2 conjugation reactions such as
N-acetylation can be equivalent to or even several-fold higher than
in the liver (Götz et al., 2012b; Kawakubo et al., 1990). Therefore, en-
zymes highly expressed in the skin such as N-acetyltransferase 1 can
be expected to play a major role in the metabolism of certain com-
pounds after topical application.
Once a compound has entered the systemic circulation, it may be
subject to hepatic metabolism. By using human hepatocyte cultures,
information can be gained as to rate of metabolism and the likelihood
of a compound being detoxiﬁed or bioactivated to reactive
intermediates (Hewitt et al., 2007). For aromatic amine hair dyes, it
has been shown that this information helps assess whether any reactive
intermediates were generated and what hepatic metabolites can be
formed (Skare et al., 2009; Nohynek et al., 2006). Likewise, we have
used human hepatocytes to investigate the systemic metabolism kinet-
ics, since the liver is themajor site of metabolism of compounds present
in the general circulation. Intrinsic clearance values determined in vitro
are often scaled to predict human hepatic clearance and even systemic
clearance (Chiba et al., 2009).
In a ﬁnal step, we used the data generated for bioavailability follow-
ing topical hair dye product application and the metabolism kinetics
from keratinocyte and hepatocyte cultures to estimate AME of the indi-
vidual compound to calculate the systemic exposure (area under the
curve (AUC)). For this purpose, we combined publicly available data
for the viable epidermis such as thickness (mean of means in Bauer
et al. (2001) and Bergstresser et al. (1978)) with the compound speciﬁc
permeability constant, kp (DermWin v2.01, corrected, (EPA and SRC))
(a measure of the rate of permeability of a compound through a tissue,
expressed in distance/time [cm/h]) to calculate the Mean Residence
Time (MRT). The average keratinocyte cell abundance per cm2
(mean of values reported by Bauer et al. (2001) and Bergstresser
et al. (1978)) was used to estimate the proportion of parent com-
pound versus metabolized compound from the keratinocyte enzyme
kinetics data.
To extrapolate further the fate of the parent compound that survived
epidermal ﬁrst pass metabolism when arriving in the systemic circula-
tion, we used the hepatocyte enzyme kinetic data in combination with
publicly available liver data for cell number per liver weight (Brown
et al., 2007) to calculate intrinsic clearance, which was combined with
liver blood ﬂow and fraction of compound unbound in the blood to
give hepatic clearance. Hepatic clearance data combined with the
remaining amount of the parent compound not metabolized in the
skin (internal dose) were then used to calculate the systemic exposure
(AUC). A conservative overestimation of the maximum systemic con-
centration (Cmax) could also be obtained using the internal dose and
the volume of distribution. The Cmax and AUC are key parameters in
physiologically based pharmacokinetic (PBPK) models for risk assess-
ment and provide a more realistic measure of exposure (dose metrics)
relevant to a mode of action (Meek et al., 2013).To test our hypothesis, wehave chosen commonly used aminophenol
hair dyes to analyze if different constellations (meta-, para- and ortho-)
of the functional amino- and hydroxy-groups have an impact on their
metabolism by using the molecules AHT (4-amino-2-hydroxytoluene),
AMC (4-amino-m-cresol) and AEP (2-amino-5-ethylphenol). Three
further important aromatic amine hair dyes were included in the
analysis, namely TDA (toluene-2,5-diamine), HDAP (1-hydroxyethyl-
4,5-diaminopyrazole) and PPD (p-phenylenediamine) (see Fig. 1 for
structures).
Materials and methods
Chemicals. AHT, AMC, AEP, TDA, HDAP and PPD were from The Procter
and Gamble Company, Darmstadt, Germany. Radiolabelled compounds
(14C-ring labeled) were from Amersham Biosciences, Buckinghamshire,
UK. All other chemicals were from Sigma-Aldrich or Applichem GmbH,
Gatersleben, Germany and were of analytical grade. For the HaCaT and
hepatocyte metabolism studies for AMC and for the HaCaT study with
HDAP, no radiolabelled dye was used. All mass numbers provided in
this paper are presented relative to free base quantities.
Instrumentation. The analysis of HaCaT and hepatocyte samples was
performed using a Waters Aquity High Performance Liquid Chro-
matograph (HPLC), a Waters Synapt Quadrupole Time-of-Flight (Q-
ToF) Mass Spectrometer and a Packard β-RAM 515A radioanalytical
detector (RAD). The mass spectrometer was used in both positive
and negative ionization modes with the “W” ﬂight path (~14,000
resolution) and summed acquired data from m/z 50–1250 once per
second. Typically 10 μL of sample were injected. Three differentWaters
Aquity columnswere used, BEH C18 1.7 μ (2.0 × 100mm), phenyl hexyl
1.7 μ (2.1 × 150mm) or BEH amide (1.7 μ 2.1 × 150mm), all with a col-
umn oven temperature of 25 °C. Column selection in each case was de-
pendent upon polarity of the substrates and their metabolites. Mobile
phase A was 5% methanol with 3 mM ammonium formate for negative
ion mode and 2% methanol with 10 mM ammonium formate for posi-
tive ion analyses. Mobile phase B was methanol in both cases, with
overall ﬂow rate 0.250 ml/min. A 2 min hold time with mobile phase
A was used and followed by a linear gradient to 80% mobile phase B at
14 min. Post-column, ~200 μL/min of the mobile phase was split to
the RAD (with 800 μL/min Perkin Elmer Ultima Gold MV® scintillant
added), and the remaining ~50 μL/min split off to themass spectrometer.
Keratinocyte (HaCaT) cell incubations. HaCaT cells – Clone B (passage 33
from Deutsches Krebsforschungszentrum (DKFZ) in Heidelberg,
Germany) were seeded into 6-well plates at 0.5 × 106 viable cells/well
in high glucose DMEM containing 10% fetal calf serum, penicillin
(10,000 units/ml) and streptomycin (10 μg/ml). After 24 h, themedium
was removed and replaced with fresh medium (low glucose DMEM
with 5% fetal calf serum with 1% penicillin–streptomycin) containing
14C-labeled test compounds (dissolved in 5% methanol in water (v/v))
which were added to the medium to give ﬁnal concentrations up to
10 μg/ml in a ﬁnal volume of 2 ml. The ﬁnal methanol concentration
was less than or equal to 0.5%. A positive control for N-acetyltransfer-
ase-1 activity, using 10 μg/ml p-aminobenzoic acid, was included in
each assay. This substrate was incubated at 37 °C from 0 to 24 h and
from 21 to 24 h (to conﬁrm the enzymes were still active at the end of
the incubation). Incubations with test compounds were at 37 °C for
24 h. Supernatants of all test items were removed after 24 h and stored
at −70 °C until analyzed. Samples from HaCaT incubations were
thawed at room temperature and then centrifuged at 4000 × g for 2 to
4 min. The loss of parent compound and formation of metabolites
were quantiﬁed using HPLC/RAD/Q-ToF/MS or HPLC/MS (AMC and
HDAP). Accurate mass identiﬁcations were made with high resolution
mass spectrometry while quantiﬁcation was performed with
radioanalytical detection, where applicable. The remaining cells were
harvested by trypsinisation and counted (Easy Count cell analyzer).
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Fig. 1. Structures of themonocyclic aromatic amine hair dye precursors tested: AHT (4-amino-2-hydroxytoluene), AMC (4-amino-m-cresol), AEP (2-amino-5-ethylphenol), TDA (toluene-
2,5-diamine), HDAP (1-hydroxyethyl-4,5-diaminopyrazole), and PPD (p-phenylenediamine).
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North Carolina, USA) were thawed according to the supplier's instruc-
tions. For cultured hepatocyte incubations, the cells were seeded at
0.35 × 106 cells per well, 0.5 ml per well, in a 24-well collagen-coated
plate. The hepatocytes were allowed to attach for 4–6 h and then cov-
ered with a layer of GelTrex (Invitrogen, California, USA) before being
incubated overnight under standard culture conditions. Cultured hepa-
tocytes were treated with the test compounds 24 h after plating using
HepatocyteMaintenanceMedia (Williams EMedia, Hepatocyte Growth
Cocktail and dexamethasone (Invitrogen)). To conﬁrm the metabolic
capacity of the hepatocytes, the metabolism of 7-ethoxycoumarin
(1000 μM) was measured. Incubations with test compounds and posi-
tive control were at 37 °C and for 24 h. Supernatants of all test items
were removed and stored at−70 °C until analyzed. Samples fromhepa-
tocyte incubations were thawed at room temperature and then centri-
fuged at 4000 × g for 2 to 4 min. The loss of parent compound and
formation of metabolites were quantiﬁed using HPLC/RAD/Q-ToF/MS
or HPLC/MS (for AMC). Accurate mass identiﬁcations were made with
mass spectrometry, while quantiﬁcation was performed with
radioanalytical detection where applicable.Ex-vivo human skin absorption and metabolism. Healthy human abdom-
inal skin (obtained from 4 female donors directly after abdominal or
breast reduction surgery) was kept on ice for no longer than 4 h prior
to the onset of the ex-vivo skin absorption and metabolism studies.
The skin was trimmed of fat and cut to a thickness of approximately
500 μm in 20 mm diameter circles. The resulting discs were mounted
onto a two-compartment static model consisting of a Netwell™ insert
(van de Sandt et al., 2004) which allowed for contact between the
basalmembrane and the receptor ﬂuid (DMEM/HamF12media supple-
mented with epidermal growth factor (10 ng/ml), hydrocortisone
(400 ng/ml), gentamycin (50 μg/ml) and fetal calf serum (10% v/v),
pH 7.5). To obtain a homogeneous distribution of the receptor ﬂuid
the 6-well plates were gently rocked on a platform in a humidiﬁed incu-
bator maintained at 32± 2 °C under an atmosphere of 5% CO2. The skin
viability was shown to be well maintained over the 24 h period, where-
byMTT (tetrazolium dye colorimetric assay for cellular growth and via-
bility)metabolism at the end of the incubation ranged between 80% and
94% of the initial activity (data not shown).
The color formulation creams (The Procter and Gamble Company,
Darmstadt, Germany) containing radiolabelled test compounds weremixed 1:1 with Welloxon Perfect (containing 6% hydrogen peroxide;
(The Procter and Gamble Company, Darmstadt, Germany)) and applied
to the skin discs at 100mgﬁnalmixture/cm2 to reﬂect usage concentra-
tions. The formulations were washed off after 60 min to mimic in-use
conditions. The washing procedure involved washing 10 times with
750 μL demineralized water; three times with 750 μL soap solution
(2% sodium dodecyl sulfate) in water; and ﬁnally with 10 washes with
750 μL demineralized water. The skin surface was then carefully dried
with three cotton swabs. The applied doses and the actual doses of
each test compound after rinsing are provided in Tables 1 (column
5) and 2 (column 3a), respectively. Receptor ﬂuid was collected at 3 h
and 24 h and frozen until analysis. After 24 h, the skin discs were
removed from the diffusion mounting, and the component layers
were separated. The stratum corneum was removed by tape-stripping
15 times. The remaining skin discs were dissolved in 1.5 M potassium
hydroxide in 20% ethanol. All skin disc samples were stored at−70 °C
until analysis.
Receptor ﬂuid samples were pooled per group and per time point
and concentrated by freeze drying overnight. The residue was
re-dissolved in approximately 300 μL of mobile phase buffer and an-
alyzed by HPLC/UV/RAD and/or HPLC/MS/MS. Parent compounds
and their metabolites were extracted from the skin discs by adding
80% methanol to the pulverized tissue and vigorously vortexing for
10 min. After centrifugation (10 min, 1800 × g at 4 °C), the superna-
tant was transferred to a clean glass tube. The extraction procedure
was repeated twice using 80% aqueous methanol, and the supernatants
from each skin membrane were pooled. An aliquot (1.2–1.8 ml) of the
organic phase was removed and evaporated under a dry stream of
nitrogen gas. The residue was reconstituted in appropriate mobile
phase and analyzed by HPLC/UV/RAD and/or HPLC/MS/MS.
Ratmetabolism data in vivo. Ratmetabolism information has been taken
from historical studies performed for regulatory purposes as previously
described (SCCS/SCCP opinions of AHT (SCCP, 2006), AMC (SCCP, 2005),
AEP (SCCS, 2012c), TDA (SCCS, 2012b), andHDAP (SCCS, 2011)). Brieﬂy,
rats were dosed orally (by gavage) and dermally with a single dose of
14C-labeled test compound. Topical application was carried out on the
shaved back of the rats attaching two ‘O’-rings to the skin resulting in
a total dosing area of 20 cm2. Animals wore collars to prevent them
from touching the dosed area and swallowing the compound. The expo-
sure was stopped by washing with shampoo and water. Urine was col-
lected pre-dose and in 0–6, 6–12, 12–24, 24–48, 48–72 and 72–96 h
Table 1
Comparison of in vitro and in vivometabolism data.
1 2 3 4 5 6
Compound/
MW [Da]
Exposure/
metabolism pathway
Human keratinocytes (HaCaT) Human hepatocytes Human skin ex vivo Rat in vivo
In vitro culturea In vitro culturea Hair dye use exposureb Oralc Dermalc
AHT
MW: 123.6
Dose unit:
Dose:
Pathway(s):
N–acetylation [%]
O–Sulfation [%]
O–Glucuronidation [%]
µg/ml
0.625 1.25 5.0 10.0
79 64 30 17
x x x x
x x x x
µg/ml
0.875 8.75 87.5
8d 18d 3
92 51 9
x 31 38
mg/cm²
1.5
86
x
x
mg/kg (mg/cm²)
100 (1.25) 100 (1.25)
32d 66d
14 14
10 14
AMC
MW: 123.16
Dose unit:
Dose:
Pathway(s):
N–acetylation [%]
O–Sulfation [%]
O–Glucuronidation [%]
µg/ml
0.492 1.476 3.08 4.92
100 87 83 100
x x x x
x x x x
µg/ml
0.86 28.62 86.2
84d 75d 69
x x x
16 25 31
mg/cm²
1.5
72
x
x
mg/kg (mg/cm²)
60 (0.75) 60 (0.75)
50d 60d
x x
41 36
AEP
MW: 137.1
Dose unit:
Dose:
Pathway(s):
µg/ml
0.50 0.99 3.96 7.9
µg/ml
0.975 9.75 97.5
mg/cm²
1.0 
mg/kg (mg/cm²)
296 64 (0.8)
N–acetylation [%]
O–Sulfation [%]
O–Glucuronidation [%]
100 100 68 41
x x x x
x x x x
17d 10d x
53 38 2
30 51 72
85
10
x
6 15
78 65
17 4
TDA
MW: 122.1
Dose unit:
Dose:
Pathway(s):
Mono–N–acetylation [%]
Di–N–acetylation [%]
µg/ml
0.35 0.70 2.8 5.6
54 60 57 52
46 40 12 5
µg/ml
0.872 8.72 87.22
35 71 100
65 3 x
mg/cm²
2.22
21
69
mg/kg (mg/cm²)
14 18 (0.3)
80 79
13 11
HDAP
MW: 142.09
Dose unit:
Dose:
Pathway(s):
N–acetylation [%]
Oxidation [%]
Deamination [%]
µg/ml
0.59 5.89 
5 5
x x
x x
µg/ml
0.994 9.94 99.4
100 57 49
x x x
x x x
mg/cm²
1.77
BLD
n.a.
n.a.
mg/kg (mg/cm²)
222 48 (0.6)
51 100
11 x
8 x
Human skin model (EpiDerm)e Human in vivof
PPD
MW: 108.1
Dose unit:
Dose:
Pathway(s):
µg/ml
0.59 5.91 
µg/ml
0.77 7.7 77.0
mg/cm²
Dose equivalent to 
3.5 
mg/kg (mg/cm²)
Average on head exposure
28.6 (3.5)
Mono–N–acetylation [%]
Di–N–acetylation [%]
11 15
89 11
x 40 3
100 16 x
10
47
<1
>90
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Table 2
Amount of parent compound expected to survive skin metabolism as it penetrates through human skin.
1 2 3a 3b 4 5 6 7 8
Dye Vmaxa [HaCaT
acetylation]
Exposureb per hair dye
event, after rinsing
Amtc penetrating
into the receptor
ﬂuid
kelm Kpcorrd MRT Estimated Amte of parent
compound surviving skin
metabolism
Measured Amtf of parent
compound surviving skin
metabolism
(μg/min/cm2) (μg eq/cm2) (μg eq/cm2) (h−1) (cm/h) (h) (μg/cm2) (μg eq/cm2)
AHT 0.0137 12.6 6.00 0.137 1.07 × 10−3 4.58 3.20 0.83
AMC 0.0022 11.6 1.27 0.102 1.07 × 10−3 4.58 0.79 0.36
AEP 0.0149 5.9 1.1 0.814 3.19 × 10−3 1.53 0.317 0.05
TDA 0.0125 51.2 15.5 0.048 4.09 × 10−4 11.93 8.72 1.61
HDAP 0.0019h 16.8 0.059 1.919 8.59 × 10−6 568 0.00 bb0.13
PPDg 0.0052h 36.7 5.5 0.056 2.45 × 10−4 19.94 1.78 1.84
AHT (4-amino-2-hydroxytoluene), AMC (4-amino-m-cresol), AEP (2-amino-5-ethylphenol), TDA (toluene-2,5-diamine), HDAP (1-hydroxyethyl-4,5-diaminopyrazole), and PPD
(p-phenylenediamine); eq = equivalent (radioactivity based).
a Fitting of data to Michaelis–Menten curve using GraphPad Prism v4.00.
b Measured skin exposure level based on radioactivity remaining on and in the skin after 60 min exposure to hair dye product and surface rinsing step (use conditions).
c Amount of radioactive dose penetrating through skin to receptorﬂuid (parent compound+metabolites) per hair dye event, based on human ex vivo skin penetration andmetabolism
studies.
d Corrected value from DermWin v2.01 (EPA and SRC).
e Rowland M, and Tozer TN, “Clinical Pharmacokinetics: Concepts and Applications”, Lea & Febiger, 1989.
f Cumulative amount of parent compound in receptor ﬂuid measured after 24 h exposure period to human skin ex vivo.
g Absorbed amount (columns 3a and3b)was from in vitro human skin equivalent penetration study;measured amount of parent compound surviving penetration andmetabolismwas
from Hu et al. (2009) after 30 min application of 36.7 μg/cm2 (exposure amount equivalent to in-use application of 2% PPD).
h TheMichaelis–Menten curvewas linear for the substrate concentrations tested. Vmaxwas approximated by calculating the velocity at the highest tested concentration, using the slope
and intercept of the linear regression line of that linear portion of the Michaelis–Menten curve.
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tion counting in selected urine samples, and the metabolite proﬁle
was investigated by HPLC/MS/MS. All procedures were performed
in AAALAC (Association for Assessment and Accreditation of Labora-
tory Animal Care) International accredited facilities and conducted
in accordance with the National Research Council's Guide for the
Care and Use of Laboratory Animals.
Analysis procedures. Michaelis–Menten parameters, Km and Vmax, were
determined from metabolism assays of the hair dyes in human
keratinocytes and hepatocytes. Non-linear regression of the in vitrome-
tabolism data of reaction velocity versus substrate concentration of the
hair dyes in these matrices was performed using GraphPad Prism v.
4.00. The non-linear regression of the data was ﬁt to the Michaelis–
Menten equation:
v ¼ Vmax  S½ = Km þ S½ ð Þ
where v is the reaction velocity, [S] is the substrate concentration, Vmax
is the reaction velocity extrapolated to very high concentrations of sub-
strate, and Km is theMichaelis–Menten constant in the same units as [S].
It is the substrate concentration needed to achieve a half-maximum re-
action velocity.
In silico estimations of the permeability constant, kp were calculated
using DermWin™ v. 2.01 software, developed by the United States En-
vironmental Protection Agency (USEPA) and Syracuse Research Corpo-
ration (SRC), which is available publicly as part of the EPISuite v. 4.11
suite of programs (USEPA).
Results
Comparison of skin and hepatic metabolism in vitro and in vivo
Table 1 summarizes the metabolism data of six aromatic amine hair
dye ingredients resulting from exposure of human keratinocytes andNotes to Table 1:
AHT (4-amino-2-hydroxytoluene), AMC (4-amino-m-cresol), AEP (2-amino-5-ethylpheno
(p-phenylenediamine); x: not detected; n.a.: not analyzed; data in italics represent dosing co
for metabolite; ain the medium after 24 h incubation; bmetabolite percentages in receptor ﬂui
72 h; dN-acetylation percentage may include further modiﬁcation at hydroxy group of mol
(2012a). The shaded area indicates in vivo rat data.hepatocyte cultures, as well as from exposure of ex vivo human skin
discs under hair dye use conditions. These data are compared to corre-
sponding historical rat data or humandata (in the case of PPD) generated
for regulatory purposes. There are known species differences in the
levels and substrate speciﬁcity of xenobiotic metabolizing enzymes
in skin (Oesch et al., 2014) and liver (Hewitt et al., 2007); however,
the metabolites of the hair dyes produced in rats in these studies
were comparable to those in the in vitro humanmodels andwere there-
fore helpful to address whether ﬁrst pass metabolism occurred in
the skin. In Table 1, all N-acetylation transformations (with or without
additional O-glucuronidation or O-sulfation) have been combined for
reporting purposes. Although we were unable to verify the speciﬁc
position of sulfation and/or glucuronidation in some cases, we refer to
O-sulfation and O-glucuronidation because there is a high likelihood
that these reactions are due to the presence of the hydroxyl group in
AHT, AMC and AEP. This is supported by the ﬁndings of Hedtke et al.
(2008) who identiﬁed the O-sulfate of AHT excreted in rats and mice
using NMR and sulfatase methodologies.
When each compound was incubated with HaCaT cells and ex vivo
human skin discs the major metabolite formed was always the N-
acetylated form of the parent compound, in line with previous ﬁndings
by our group (Goebel et al., 2009) and others (Eggenreich et al., 2004).
This shows the prevalence of theN-acetylation pathway in the skin, par-
ticularly the viable epidermis. As the exposure concentration in HaCaT
cultures increased, the percentage of N-acetylated AHT decreased,
indicating that this pathway can be saturated. In human hepatocytes,
N-acetyl-AHT was also produced but was not a major metabolite; in-
stead, AHT-O-glucuronide and/or AHT-O-sulfate were mainly gener-
ated. The ratio of each metabolite depended on the dose (more
sulfation and less glucuronidation at lower doses and vice versa at high
doses). Similar metabolic pathways of N-acetylation, O-glucuronidation
and O-sulfation were also found in rat in vivo studies.
As with AHT, AMC was a good substrate for N-acetylation by HaCaT
cells across all doses tested.When exposed to ex vivo human skin under
hair dye use conditions the only metabolite identiﬁed was N-acetyl-l), TDA (toluene-2,5-diamine), HDAP (1-hydroxyethyl-4,5-diaminopyrazole), and PPD
ncentration; data in normal font represent percent of accumulated radioactivity speciﬁc
d after 60 min skin exposure collected for 24 h; cin combined urine samples collected for
ecule (i.e. O-sulfation, O-glucuronidation); data taken from eHu et al. (2009); or fSCCS
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O-glucuronidated metabolites of AMC. The amount of glucuronidated
metabolites increased with increasing doses. This metabolite spectrum
was also present following dermal and oral exposure of rats, with a
higher contribution of N-acetylation following dermal exposure.
In addition toN-acetylation, AEP was sulfated in ex vivo human skin,
whereby 10% of the dose administered was detected in the receptor
ﬂuid as the sulfamic acid. This indicates that for aromatic amines meta-
bolic pathways other than N-acetylation can occur in the skin, but are
quantitatively considered less relevant under the applied hair dye expo-
sure conditions. The sulfation of AEP in human skin and its prevalence in
dermal and oral rat studies show that this compound can be considered
a good substrate for sulfotransferase enzymes. In human hepatocytes,
AEP was metabolized via three main conjugation pathways, namely N-
acetylation, O-sulfation and O-glucuronidation. The percent of the
dose converted to AEP-O-sulfate and N-acetyl-AEP-glucuronide de-
creasedwith increasing concentrations. By contrast, the relative amount
of AEP-glucuronide increased as the concentration of AEP increased.
The three main conjugation pathways were also observed in rats fol-
lowing oral and dermal administration, with a higher contribution of
N-acetylation and a lower portion of O-glucuronidation exhibited
following dermal exposure.
HaCaT cells converted 52–60% of TDA to 5-acetyl-TDA at all concen-
trations tested. Higher concentrations of the di-acetylated TDA (69%)
were found following exposure of human skin ex vivo under hair dye
conditions, while 21% were mono-acetylated. By contrast, the relative
amount of mono-acetylated metabolite produced by human hepato-
cytes increased with increasing concentrations of TDA. Further N-
acetylation of 5-acetyl-TDA by both hepatocytes and HaCaT cells de-
creased as the concentration increased. Similarly, in rats, mono-N-Table 3
Extrapolation of systemic exposure of select hair dyes (parent compounds) after dermal applic
1 2 3 4 5a
Compound Vmax [hepatic]
(nmol/min/106 cells)
Km
(μM)
Vmax/Km
(ml/min/106 cells)
Scaled CLint
(ml/min/kg)
N-acetylation
AHT 0.02 157.80 1.52 × 10−4 0.47
AMC Slopeb=N 6.80 × 10−4 2.10
AEP 1.40 5785 2.43 × 10−4 0.75
TDA 65.52 60,906 1.08 × 10−3 3.32
HDAP Slopeb=N 5.40 × 10−4 1.67
PPD 10.28 21,252 4.84 × 10−4 1.51
Sulfation
AHT 0.06228 56.31 1.11 × 10−3 3.41
AMC No sulfation seen- –
AEP 0.1946 362.5 5.37 × 10−4 1.66
TDA No sulfation seen –
HDAP No sulfation seen –
PPD No sulfation seen –
Glucuronidation
AHT Slopeb=N 3.82 × 10−4 1.18
AMC Slopeb=N 3.12 × 10−4 0.96
AEP Slopeb=N 7.26 × 10−4 2.24
TDA No glucuronidation seen –
HDAP No glucuronidation seen –
PPD No glucuronidation seen –
Total
AHT Total=N 5.06
AMC Total=N 3.06
AEP Total=N 4.65
TDA Total=N 3.32
HDAP Total=N 1.67
PPD Total=N 1.51
AHT (4-amino-2-hydroxytoluene), AMC (4-amino-m-cresol), AEP (2-amino-5-ethylpheno
(p-phenylenediamine).
a Calculated Amt of Parent compound surviving metabolism from Table 2, column 7 multipl
b The Michaelis–Menten curve was linear for the substrate concentrations tested. The slopeacetylation was via 5-acetyl-TDA, which was further acetylated at the
2-position to form the di-acetylated metabolite. The relative ratio of
the total N-acetylated TDA metabolites to parent compound was very
similar in all humanmodels tested i.e. HaCaT cells, ex vivo skin explants
and hepatocytes. This suggests no differences in themetabolite ratio be-
tween topically and systemically applied TDA, in line with the rat data
(Table 1, column 6). Consequently, when entering the living skin the
majority of TDA is consumed via this pathway, as indicated by the rate
of N-acetylation in HaCaT cells, in line with limited amount of parent
found following ex vivo human skin exposure (Table 2, columns 7 and
8). When systemically available, the human hepatocyte data indicate
that the rate of N-acetylation further reduces the amount of parent
TDA (Table 3, column 2) and that this is the only relevant metabolic
pathway (Table 1, column 4) in line with previously published data
(Skare et al., 2009).
The N-acetylated metabolite of HDAP was produced by HaCaT cells
and human hepatocyte cultures. Although the relative amount of
HDAP that was N-acetylated by HaCaT cells was low (5%), it was not
affected by a 10-fold increase in concentration. By contrast, there was
a decrease in the percent of N-acetylated HDAP produced in human
hepatocytes with increasing concentrations. It was not possible to
determine whether ex vivo whole skin produced this metabolite, due
to the very low skin penetration of HDAP (Table 2, column 3b). As a
result of the slow migration of HDAP through the viable epidermis
(estimated MRT was very high; Table 2, column 6) in combination
with a high likelihood of epidermal N-acetylation indicated by the cor-
responding HaCaT activity (Table 2, column 2), we assume that only
the N-acetyl metabolite is able to enter the systemic circulation
(Table 2, columns 7 and 8). This is in line with the oral rat study, in
which the N-acetyl metabolite was the major metabolite producedation.
5b 6 7
Hepatic clearance CLH
(ml/min/kg)
Total Amt parent compound
surviving skin metabolisma (μg)
Parent compound AUC
(μg·h/ml)
0.13 1856 3.44
0.55 461 0.20
0.16 184 0.27
1.23 5058 0.98
0.69 0 0
0.61 1035 0.41
0.90 1856 0.49
461
0.35 184 0.12
5058
0
1035
0.32 1856 1.39
0.26 461 0.43
0.48 184 0.09
5058
0
1035
1.34 1856 0.33
0.81 461 0.14
0.99 184 0.04
1.23 5058 0.98
0.69 0 0
0.61 1035 0.41
l), TDA (toluene-2,5-diamine), HDAP (1-hydroxyethyl-4,5-diaminopyrazole), and PPD
ied by average scalp application area of 580 cm2 (SCCS, 2012d).
in the linear portion of the curve approximates Vmax/Km.
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lowing dermal exposure was N-acetyl-HDAP, which was also the
major metabolite following oral exposure. However, the analysis of uri-
nary HDAP metabolites was difﬁcult due to chemical degradation and a
low amount of excreted radioactivity.
N-acetylation was also the main route of PPD metabolism in
HaCaT and hepatocyte incubations, both converting the entire
amount of the parent at the low concentrations with 89% and 100%
detected as di-N-acetyl-PPD, respectively. Therefore, we assume
that only the N-acetyl metabolite is able to enter the systemic circula-
tion. The degree of N-acetylation per PPD molecule is concentration-
dependent and the di-acetylation activity is likely to become saturated
at higher PPD concentrations i.e. the highest rate was observed at the
lowest concentration tested (89%) and decreased with increasing con-
centrations. The Epiderm™ results provided for the high dermal dose
of 36.7 μg/cm2 conﬁrmed that at high dermal exposure the majority of
the PPD-related radioactivity was present only in its N-acetylated
forms (57%), with the di-acetylated portion being 5-fold greater than
the mono-acetylated one (Table 1, column 5), while at lower dermal
doses (1.5 μg/cm2 equivalent to 100 μM) the di-acetylated portion
was increased further to 90% and no PPD was detected in the recep-
tor ﬂuid (Hu et al., 2009). This is similar to the ﬁndings with TDA
exposure to ex vivo human skin indicating a more than 3-fold greater
di-acetylation rate compared to mono-acetylation (i.e. 69% versus
21%, Table 1, column 5). This is also in line with the ﬁndings for
TDA and with published human data on PPD in vitro and in vivo
(Nohynek et al., 2004, 2006; Hu et al., 2009; SCCS, 2012b). PPD was
onlymetabolized byN-acetylation in human hepatocytes with decreas-
ing production of the di-N-acetylatedmetabolite at increasing substrate
concentrations (Table 1, column 4). The data available for PPDmetabo-
lism generated using a 3D reconstructed skin model, Epiderm™, with a
limited barrier function compared to human skin ex vivo, indicate that
47% was converted to di-N-acetyl-PPD and 10% was mono-acetylated
under hair dye use conditions (Hu et al., 2009). Moreover, the avail-
able human data showed that more than 90% of the PPD detected
in the urine of volunteers after a hair dyeing process represent the di-
acetylated metabolite, while only less than 1% was mono-acetylated
(SCCS, 2012a).
Overall, these results show that these three phase II enzyme path-
ways are present both in vitro and in vivo, whereby the relative posi-
tion of the amino and the hydroxyl groups (i.e. representing m, p-
and o-aminophenol, respectively), impacts which phase II metabo-
lism is most relevant (see Fig. 1).
Impact of skin absorption and skinmetabolism on extrapolation of systemic
availability
Based on the HaCaT keratinocyte metabolism data (Table 1, column
3) and skin absorption data (Table 2, column 3b), it was possible to
estimate the amount of the parent hair dye that would survivemetabo-
lism in the viable epidermis and reach the general circulation un-
changed. First, the Vmax values from the HaCaT metabolism studies
were approximated from the determined reaction velocities and sub-
strate concentrations in the studies.
The calculated Vmax values, whichwere in units of nmol parent com-
pound metabolized/min/million keratinocytes, were scaled to units of
μg parent compound/min/cm2 surface area. This was done using the
molecular weight of the compound and the cell abundance in the viable
epidermis (6.02 × 106 cells/cm2 surface area) (mean of means in Bauer
et al. (2001) and Bergstresser et al. (1978)). Vmax data exhibited values
ranging from 0.0019 μg/min/cm2 for HDAP to 0.0149 μg/min/cm2 for
AEP (Table 2, column 2).
Next, using the amount of radioactivity absorbed (Amtabs) from the
ex vivohuman skin absorption data (Table 2, column3b), an approxima-
tion of the elimination rate constant, kelm (Table 2, column4)wasmade,
by taking the ratio of Vmax to Amtabs. Thiswas then converted fromunitsofmin−1 to units of h−1. The kelm values ranged from 0.048 h−1 for TDA
to 1.919 h−1 for HDAP. The rank was HDAP N AEP N AHT N AMC N
PPD N TDA. These values alone do not allow a prediction of the in vivo
skin metabolism of the particular aromatic amine hair dyes. That num-
ber would be dependent upon the length of time that the hair dye was
actually present in the viable epidermis.
Next, a value for the permeability constant, kp, can be obtained,
either directly or by using DermWin v. 2.01. It was then possible to
estimate amean residence time (MRT) for the compound being present
in the viable epidermis by dividing its thickness, 48.8 μm (mean of
means in Bauer et al. (2001) and Bergstresser et al. (1978)), by the kp.
The MRT is in units of h. HDAP was estimated to reside in the epider-
mis the longest, for almost 570 h. The shortest residing compound
was AEP, leading to the following rank order for the MRT: HDAP N N
PPD N TDA N AHT ~ AMC N AEP (Table 2, column 6).
Finally, the amount of the compound which would be expected to
penetrate the skin and survive metabolism in the viable epidermis
was estimated (with units of μg/cm2) using the following pharmacoki-
netic equation:
Amt parent compound penetrating ¼ Amtabs  e ‐kelmMRTð Þ:
Values for the estimation of parent compound penetrating the
skin are in Table 2, column 7. Relative to each other by rank and
value, they were similar to the values from the ex vivo skin absorption/
metabolism studies (TDA N AHT N PPD N AMC N AEP N HDAP; Table 2,
columns 7 and 8). The values of the extrapolated numberswere actually
higher than the ex vivo absorption/metabolism numbers.
Extrapolation of the systemic exposure (AUC)
The amount of the parent aromatic amine hair dye that would
survivemetabolism in the viable epidermis and reach the general circu-
lation unchanged was estimated using the process described above.
After the compound reaches the general circulation, its systemic expo-
sure can be calculated. The Vmax and Km values from the hepatocyte
metabolism studies (Table 3, columns2 and3, respectively)were approx-
imated from the determined reaction velocities and substrate concentra-
tions using Graphpad Prism v. 4.00.
Intrinsic clearance, CLint, (ml/min/million cells) was calculated by
dividing the Vmax by the Km (Table 3, column 4). This intrinsic clearance
(Table 3, column 5a), was scaled from Vmax/Km using reported values of
liver cell abundance (120 × 106 cells/g liver, (Brown et al., 2007)) and
mass for adult livers (26 g human liver/kg BW (Davies and Morris,
1993)):
CLint ¼ Vmax=Kmx 120 x 106cells=g liver x 26 g human liver=kg BW
final units of ml=min=kg BW½ :
Hepatic clearance (CLH) was then calculated (Table 3, column 5b)
from this scaled intrinsic clearance (CLint) using the following formula:
CLH ¼ Q x fub x Clintð Þ= Q þ fubx Clintð Þ
where Q is the liver blood ﬂow, and fub is the fraction of the com-
pound unbound in the blood. CLH by N-acetylation ranged from
0.13 for AHT to 1.2 ml/min/kg for TDA. CLH by O-sulfation was only
observed in incubations with AEP and AHT and the rate of sulfation
of AHT was a little more than twice that of AEP. The rate of hepatic
glucuronidation was in the rank order of AEP N AHT N AMC. The
range of hepatic metabolism rates, as determined by hepatic clear-
ance, was similar for N-acetylation, O-sulfation and O-glucuronidation.
The total hepatic clearance (N-acetylation, O-sulfation and O-
glucuronidation) was highest for AHT and was approximately 2-
fold higher than that of PPD.
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clearances of the body and can be conservatively estimated using the
value for CLH.
If it is assumed that the amount of the parent compound that
survives metabolism in the skin and penetrates to the general circula-
tion (Table 2, column 7 multiplied by the average scalp application
area (580 cm2 for a 70 kg adult)) is the internal dose, then the calculated
AUCwould be that dose divided by the total clearance (AUC= internal
dose/CLT). These expected values ranged from 0.0 μg·h/ml for HDAP to
nearly 0.98 μg·h/ml for TDA. The internal dose used in this calculation
already includes the fraction of dose reaching the systemic circulation,
calculated above (Table 3, column 6).
Another pharmacokinetic exposure parameter that can be
estimated is the Cmax. Using PPD as an example, we calculated
the largest estimation of this parameter (a conservative overestima-
tion) by dividing the dose (1035 μg) by the volume of distribution
(0.55 L/kg ∗ 70 kg ∗ 1000 ml/L) leading to a Cmax of 0.027 μg/ml. For
estimating the volume of distribution, Vd, the algorithm of Poulin and
Theil (2002) can be used with inputs of logP, pKa and plasma protein
binding. The estimation of these latter parameters was obtained by
the following software: logP using DermWin v. 2.01, pKa values using
ACD v. 12.0 and plasma protein binding using ChemSilico v. 1.6.1.
Using CLT and Vd, the elimination rate constant, kelm, and the half-
life, t1/2, were calculated using the following equations:
kelm ¼ CLT=Vd  0:16 h‐1 for PPD
t1=2 ¼ 0:693=kelm  4:2 h for PPD:
Discussion
We describe here how a combination of data on skin penetration
and epidermal and systemic metabolic conversion of six aromatic
amine hair dyes generated in vitro using human skin explants, human
keratinocyte (HaCaT) and hepatocyte cultures; can be applied to predict
the human AME properties, including an estimation of the systemic
exposure (AUC) following a typical hair dye application.
In a ﬁrst step, HaCaT cellswere exposed to increasing concentrations
of the hair dye constituents to estimate theirmetabolism in human skin.
Qualitatively, the HaCaT data reﬂectwell thatN-acetylation is themajor
metabolic process in the skin for the aromatic amine hair dyes. The
relevance of the HaCaT metabolism results for human exposure was
conﬁrmed by the human skin ex vivo experiments applying hair dye
use conditions (Table 1). In parallel, we determined the absorption of
each test compound using ex vivo human skin explants. The design of
these studies was to mimic the in-use conditions of hair dyeing, so
that the amount absorbed can be considered to represent a relevant
exposure level of a hair dyeing event (Rogiers and Pauwels, 2008).
Determination of dermal absorption by skin penetration is the widely
accepted method to analyze the systemic exposure to topically applied
chemicals and/or their metabolites (OECD TG28, 2004). Analysis of skin
absorption is based onmeasuring the rate of penetration into the recep-
tor ﬂuid and represents the systemically available fraction and can thus
be related to Cmax and AUC. Since the application reﬂects the exposure
scenario in real life (as in these studies) then this is directly related to
the expected plasma kinetics. Instead of using frozen skin (i.e. the stan-
dard absorption model), metabolically active living ex vivo human skin
was chosen to determine the absorption rate in order to additionally
generate direct skin metabolism data for comparison with the HaCaT
results. For this purpose, the average skin exposure time of 30 min of
a typical hair coloring treatment was increased to 60 min.
Quantitatively, the prediction of the amount of parent compound
surviving metabolism as it migrates through the skin is dependent
upon the rates of skin penetration and metabolism as well as the
length of time that the compound is actually in the presence of thekeratinocytes, i.e. the MRT in the skin. Consequently, predicted high
parent compound survival rates were afforded by low metabolism
rates and short MRTs. Only one compound (HDAP) was predicted to
not survive penetration and metabolism in the skin likely due to a low
penetration amount, a high metabolism rate and a long MRT. The com-
pound that exhibited the highest survival was TDA (8.7 μg/cm2; Table 2,
column7), because the skin penetration amountwas highwhilemetab-
olism rate was low and MRT was moderate.
Comparing the predicted values for the amount of parent compound
surviving the skin passage extrapolated from combining theHaCaT data
and skin absorption rate from the human skin ex vivo study (Table 2,
column 7) to those measured in the human skin ex vivo study by
subtracting the radioactivity identiﬁed as metabolite(s) from the total
radioactivity absorbed (Table 2 column 8) showed reasonable accor-
dance, i.e. were within the same order of magnitude. In fact, the esti-
mated values were higher than the measured values (Table 2, columns
7 and 8), indicating that the combination of HaCaT data and skin ab-
sorption rate provides a sufﬁciently conservative estimation of the con-
centration of unchanged parent compound available for entering the
systemic circulation when used for risk assessment purposes.
Finally, considering hepatic metabolism in addition to ﬁrst pass skin
metabolism revealed their substantial impact for extrapolation of the
systemic exposure to the parent hair dye compounds leading to low
predicted AUC values in the range of no parent compound remaining
for HDAP to levels between 0.04 and 0.33 μg·h/ml for the aminophenols
(AHT, AMC, AEP). Predicted AUC values for parent PPD and TDA were
0.41 and 0.98 μg·h/ml, respectively, and can be directly related to mea-
sured AUC values reported for human volunteers after applying either
[14C]-PPD or [14C]-TDA under typical hair dye use conditions (SCCS,
2012a,b). These studies showed similar total absorption of radioactivity
(measured by 14C AUCs), i.e. 14C AUC0−∞ was 1.42 μg eq·h/ml for
2% PPD and 1.85 μg eq·h/ml for 2.24% TDA. For PPD, the reported
14C-based Cmax and t1/2 were 0.13 μg eq/ml and 7.8 h, respectively,
and are considered to be in agreement with our predicted values of
0.027 μg/ml for Cmax and of 4.2 h for t1/2 for the remaining parent PPD.
The conservative agreement of our predicted AUC and Cmax values
with the published in vivo data is taking into account that in the
human studies at least more than 90% of the 14C present in plasma or
urine was found to be mono- or di-acetyl-PPD (SCCS, 2012a), showing
the overwhelming emphasis of the N-acetylation metabolic pathway.
Correspondingly, the 14C-based elimination encompasses the metabo-
lites formed plus parent compound and is therefore greater than that
for the parent compound only. Consequently, any dermally absorbed
parent compound is highly likely to be quicklymetabolized (N-acetylat-
ed), and both the total, plasma, parent compound to 14C AUC ratio and
the total, urinary, parent compound to 14C ratiowould each be expected
to be very small, if even discernible, in line with our prediction (Table 3,
column 7). Due to the close structural similarity to PPD nearly identical
kinetics and metabolism rates are very likely to occur for TDA, and
therefore very low levels of parent compound would be expected in
the plasma and urine of hair dye consumers, again in line with our
prediction.
In conclusion, we have provided evidence that a combination of
in vitro dermal penetration information with in vitro keratinocyte and
hepatocyte metabolism rates can enable predictions of the systemic
exposure to an aromatic amine hair dye applied under use conditions
that are in line with in vivo data from humans and rats. This was
achieved by applying an alternative toxicokinetic approach (see Fig. 2)
resulting in systemic exposure (AUC) estimates considered as sufﬁ-
ciently conservative for risk assessment purposes. Furthermore, the
metabolic detoxiﬁcation pathways observed are in line with the ab-
sence of toxicologically relevant ﬁndings at concentrations correspond-
ing to consumer exposure as described in the opinions released by the
scientiﬁc advisory board of the European Union (SCCP, 2006, 2005;
SCCS, 2011, 2012a,b,c). Therefore, this approach is considered a reliable
tool applicable for structure activity relationship (SAR) considerations
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Fig. 2. Process for estimating the systemic exposure of a dermally applied compound. Firstly, the 14C penetration rate of the radiolabelled compound through skin is determined or calcu-
lated. Secondly, reduction of parent compound by skinmetabolism in the viable epidermis is determined by themetabolism rate (kelm) of the keratinocytes and themean residence time
(MRT) that the compound is in the keratinocyte environment. Once the remaining parent compound arrives in the general circulation the assumed major clearance process is by liver
metabolism,which conservatively estimates total clearance, CLT. The systemic exposure is pharmacokinetically determined as theAUC, i.e. the quotient of the amount of parent compound
surviving penetration through the skin, divided by CLT. An estimation of the volume of distribution (Vd) can be obtained using in silico tools (Poulin and Theil, 2002), and can then be
applied to calculate the largest Cmax. aUsing DermWin v2.01 (EPA and SRC); bRowland and Tozer, 1989; cBrown et al., 2007; dDavies and Morris, 1993; and eusing the algorithm of Poulin
and Theil (2002). The following softwarewas used for estimating: LogP using DermWin v. 2.01, pKa values using ACD v. 12.0 (Advanced Chemistry Development, Inc.) and plasma protein
binding using ChemSilico v. 1.6.1.
147J. Manwaring et al. / Toxicology and Applied Pharmacology 287 (2015) 139–148and read-across from data rich substances (like the 5 aromatic amine
hair dyes presented in this publication) to similar structures that will
have to be assessed in non-animal approaches for their use in cosmetic
products. The ability to comparatively apply the presented approach toassess the systemic exposure of the new compound of interest versus
a well characterized one allows for a higher degree of conﬁdence in a
weight-of-evidence toxicological characterization based on non-
animal data (Blackburn and Stuard, 2014).
148 J. Manwaring et al. / Toxicology and Applied Pharmacology 287 (2015) 139–148The kp values designate the rate of movement of the hair dye
through the skin into the receptor ﬂuid. The ex vivo skin studies utilized
a minimal time course of penetration of the compounds of interest
through the skin into the receptor ﬂuid. Both of these kinetic pictures,
and even better description of the rates of movement into the receptor
ﬂuid, should enable a more direct approximation of plasma kinetics. In
the future, incorporating these penetration kinetic characteristics and
in vitro skinmetabolismparameterswill be included in a physiologically
based pharmacokinetic (PBPK) model to describe the systemic expo-
sure of chemicals applied to the skin and entering the general circula-
tion. Completion of the initial steps has been described (Dancik et al.,
2013) and integration of appropriate in vitro skin metabolism and
penetration parameters as discussed in this manuscript is in progress
to enhance the robustness of the PBPK model in line with the WHO
IPCS guidance on their characterization and application in risk assess-
ment (Meek et al., 2013). The aim is to further improve the prediction
of the internal exposure of product ingredients by utilizing dynamic
processes occurring in physiologically relevant compartments within
the body with the goal to allow for more precise risk assessments.
Conﬂict of interest
There was no conﬂict of interest among any of the authors.
References
Bauer, J., Bahmer, F.A.,Wörl, J., Neuhuber, W., Schuler, G., Fartasch, M.A., 2001. A strikingly
constant ratio exists between Langerhans cells and other epidermal cells in human
skin. A stereologic study using the optical disector method and the confocal laser
scanning microscope. J. Invest. Dermatol. 116 (2), 313–318.
Bergstresser, P.R., Pariser, R.J., Taylor, J.R., 1978. Counting and sizing of epidermal cells in
normal human skin. J. Invest. Dermatol. 70 (5), 280–284.
Blackburn, K., Stuard, S.B., 2014. A framework to facilitate consistent characterization of
read across uncertainty. Regul. Toxicol. Pharmacol. 68, 353–362.
Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Markham, A., Fusenig, N.E.,
1988. Normal keratinization in a spontaneously immortalized aneuploid human
keratinocyte cell line. J. Cell Biol. 106 (3), 761–771.
Brown, H.S., Grifﬁn, M., Houston, J.B., 2007. Evaluation of cryopreserved human hepato-
cytes as an alternative in vitro system to microsomes for the prediction of metabolic
clearance. Drug Metab. Dispos. 35 (2), 293–301.
Chiba, M., Ishii, Y., Sugiyama, Y., 2009. Prediction of hepatic clearance in human from
in vitro data for successful. Drug development. AAPS J. 11 (2), 262–276.
Dancik, Y., Troutman, J.A., Jaworska, J., 2013. A framework incorporating the impact
of exposure scenarios and application conditions on risk assessment of chemicals ap-
plied to skin. In Silico Pharmacol. 1 (1), 10.
Davies, B., Morris, T., 1993. Physiological parameters in laboratory animals and humans.
Pharm. Res. 10 (7), 1093–1095.
Eggenreich, K., Golouch, S., Töscher, B., Beck, H., Kuehnelt, D., Wintersteiger, R., 2004.
Determination of 4-amino-m-cresol and 5-amino-o-cresol and metabolites in
human keratinocytes (HaCaT) by high-performance liquid chromatography with
DAD and MS detection. J. Biochem. Biophys. Methods 61 (1–2), 23–34.
Goebel, C., Hewitt, N.J., Kunze, G., Wenker, M., Hein, D.W., Beck, H., Skare, J., 2009. Skin
metabolism of aminophenols: human keratinocytes as a suitable in vitro model to
qualitatively predict the dermal transformation of 4-amino-2-hydroxytoluene
in vivo. Toxicol. Appl. Pharmacol. 235 (1), 114–123.
Götz, C., Pfeiffer, R., Tigges, J., Ruwiedel, K., Hübenthal, U., Merk, H.F., Krutmann, J.,
Edwards, R.J., Abel, J., Pease, C., Goebel, C., Hewitt, N., Fritsche, E., 2012a. Xenobiotic
metabolism capacities of human skin in comparison with a 3D-epidermis model
and keratinocyte-based cell culture as in vitro alternatives for chemical testing:
phase II enzymes. Exp. Dermatol. 21 (5), 364–369.
Götz, C., Pfeiffer, R., Tigges, J., Blatz, V., Jäckh, C., Freytag, E.M., Fabian, E., Landsiedel, R.,
Merk, H.F., Krutmann, J., Edwards, R.J., Pease, C., Goebel, C., Hewitt, N., Fritsche, E.,
2012b. Xenobiotic metabolism capacities of human skin in comparison with a 3D
epidermis model and keratinocyte-based cell culture as in vitro alternatives for
chemical testing: activating enzymes (Phase I). Exp. Dermatol. 21 (5), 358–363.Hedtke, B., Gao, Z., Chen, L.J., Weber, W.M., Dix, K.J., 2008. Metabolism and disposition of
[14C]5-amino-o-cresol in female F344 rats and B6C3F1 mice. Xenobiotica 38 (2),
171–184.
Hewitt, N.J., Lechón, M.J., Houston, J.B., Hallifax, D., Brown, H.S., Maurel, P., Kenna, J.G.,
Gustavsson, L., Lohmann, C., Skonberg, C., Guillouzo, A., Tuschl, G., Li, A.P., LeCluyse,
E., Groothuis, G.M., Hengstler, J.G., 2007. Primary hepatocytes: current understanding
of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical
practice for the use of hepatocytes in metabolism, enzyme induction, transporter,
clearance, and hepatotoxicity studies. Drug Metab. Rev. 39 (1), 159–234.
Hu, T., Bailey, R.E., Morrall, S.W., Aardema, M.J., Stanley, L.A., Skare, J.A., 2009. Dermal
penetration andmetabolism of p-aminophenol and p-phenylenediamine: application
of the EpiDerm™ human reconstructed epidermis model. Toxicol. Lett. 188 (2),
119–129.
Kawakubo, Y., Ohkido, M., 1998. Epidermal N-acetylation of p-aminobenzoyl glutamic
acid: difference in response to ultraviolet B irradiation. J. Dermatol. Sci. 16 (2),
99–103.
Kawakubo, Y., Yamazoe, Y., Kato, R., Nishikawa, T., 1990. High capacity of human skin for
N-acetylation of arylamines. Skin Pharmacol. 3 (3), 180–185.
Kawakubo, Y., Merk, H.F., Masaoudi, T.A., Sieben, S., Blömeke, B., 2000. N-Acetylation of
paraphenylenediamine in human skin and keratinocytes. J. Pharmacol. Exp. Ther.
292 (1), 150–155.
Meek, M.E., Barton, H.A., Bessems, J.G., Lipscomb, J.C., Krishnan, K., 2013. Case study illus-
trating theWHO IPCS guidance on characterization and application of physiologically
based pharmacokinetic models in risk assessment. Regul. Toxicol. Pharmacol. 66 (1),
116–129.
Nohynek, G.J., Skare, J.A., Meuling, W.J., Hein, D.W., De Bie, A.T., Toutain, H., 2004. Urinary
acetylated metabolites and N-acetyltransferase-2 genotype in human subjects
treated with a paraphenylenediamine-containing oxidative hair dye. Food Chem.
Toxicol. 42, 1885–1891.
Nohynek, G.J., Duche, D., Garrigues, A., Meunier, P.A., Toutain, H., Leclaire, J., 2006. Under
the skin: biotransformation of para-aminophenol and para-phenylenediamine in
reconstructed human epidermis and human hepatocytes. Toxicol. Lett. 158, 196–212.
OECD 428, 2004. OECD Guideline for Testing of Chemicals— Guideline 428: Skin Absorp-
tion: In Vitro Method. Organization for Economic Cooperation and Development,
Paris (adopted 13 April 2004).
OECD TG28, 2004. OECD Guidance Document for the Conduct of Skin Absorption Studies.
OECD series on testing and assessment No. 28 (5 March, 2004).
OECD TG427, 2004. OECD Guidelines for Testing of Chemicals, Section 4, Health Effects,
Number 427: “Percutaneous Absorption: In Vivo Method” (adopted April 13, 2004).
Oesch, F., Fabian, E., Oesch-Bartlomowicz, B., Werner, C., Landsiedel, R., 2007. Drug-
metabolizing enzymes in the skin of man, rat, and pig. Drug Metab. Rev. 39 (4),
659–698.
Oesch, F., Fabian, E., Guth, K., Landsiedel, R., 2014. Xenobiotic-metabolizing enzymes in
the skin of rat, mouse, pig, guinea pig, man, and in human skin models. Arch Toxicol.
88 (12), 2135–2190.
Poulin, P., Theil, F.-P., 2002. Prediction of pharmacokinetics prior to in vivo studies. 1.
Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91 (1), 129–156.
Rogiers, V., Pauwels, M., 2008. Safety assessment of cosmetics in Europe. In: Itin, P. (Ed.),
Safety Assessment of Cosmetics in Europe vol. 36. Karger, Basel, New York, pp. 36–40
(Chapter 2).
Rowland, M., Tozer, T.N., 1989. Clinical Pharmacokinetics: Concepts and Applications. Lea
& Febiger, Philadelphia, p. 66.
SCCP (Scientiﬁc Committee on Consumer Products), 2005. Opinion on 4-amino-m-cresol,
20 September 2005.
SCCP (Scientiﬁc Committee on Consumer Products), 2006. Opinion on 4-amino-2-
hydroxytoluene, 10 October 2006.
SCCS (Scientiﬁc Committee on Consumer Safety), 2011. Opinion on 1-hydroxyethyl-4,5-
diaminopyrazole sulphate, 13–14 December 2011.
SCCS (Scientiﬁc Committee onConsumer Safety), 2012a. Opinion onp-phenylenediamine,
26–27 June 2012.
SCCS (Scientiﬁc Committee on Consumer Safety), 2012b. Opinion on toluene-2,5-diamine
and its sulfate, 26–27 June 2012.
SCCS (Scientiﬁc Committee on Consumer Safety), 2012c. Opinion on 2-amino-5-
ethylphenol HCl, 27 March 2012.
SCCS (Scientiﬁc Committee on Consumer Safety), 2012d. The SCCS's Notes of Guidance
for the Testing of Cosmetic Substances and Their Safety Evaluation 8th Revision, 11
December 2012.
Skare, J.A., Hewitt, N.J., Doyle, E., Powrie, R., Elcombe, C., 2009. Metabolite screening of
aromatic amine hair dyes using in vitro hepatic models. Xenobiotica 39 (11), 811–825.
van de Sandt, J.J., van Burgsteden, J.A., Cage, S., Carmichael, P.L., Dick, I., Kenyon, S.,
Korinth, G., Larese, F., Limasset, J.C., Maas, W.J., Montomoli, L., Nielsen, J.B., Payan,
J.P., Robinson, E., Sartorelli, P., Schaller, K.H., Wilkinson, S.C., Williams, F.M., 2004. In
vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a
multi-centre comparison study. Regul. Toxicol. Pharmacol. 39 (3), 271–281.
